{
    "clinical_study": {
        "@rank": "84251", 
        "brief_summary": {
            "textblock": "To determine cell cycle parameters and changes after treatment, the labelling agent is given\n      and a bone marrow aspiration is accomplished before treatment and after treatment for\n      comparison. Participants must be undergoing concurrent therapy for hematologic malignancy."
        }, 
        "brief_title": "IUdR/BUdR Cell Cycle Labelling", 
        "completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "condition": "Hematologic Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and\n      differences between normal and leukemic cells in patients with hematologic malignancy prior\n      to and following treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Histologic proof of one of:\n\n          -  AML, ALL, or AUL\n\n          -  MDS or CMML\n\n          -  CML\n\n          -  OR undergoing bone marrow transplantation.\n\n        Participants should be:\n\n          -  off therapy for at least two weeks\n\n          -  At least 18 years old or older\n\n          -  Using adequate contraception if of child-bearing capability."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00042250", 
            "org_study_id": "DM91-102"
        }, 
        "intervention": {
            "intervention_name": "Chemotherapy for hematologic malignancy", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cell Cycle Interphase", 
            "G0", 
            "G1", 
            "G2", 
            "S Phase"
        ], 
        "lastchanged_date": "January 20, 2012", 
        "link": {
            "description": "M. D. Anderson Cancer Center", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M.D. Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Michael Andreeff, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042250"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 1992", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2012"
    }, 
    "geocoordinates": {
        "M.D. Anderson Cancer Center": "29.76 -95.369"
    }
}